Suven Pharmaceuticals Limited (NSE:SUVENPHAR)

Suven Pharmaceuticals Income Statement

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020
Operating Revenue	10,485	10,514	13,403	13,202	10,097	8,338
Other Revenue	-	-	-	-	-0	-
Revenue	10,485	10,514	13,403	13,202	10,097	8,338
Revenue Growth (YoY)	-10.21%	-21.56%	1.52%	30.75%	21.10%	-8.05%
Cost of Revenue	3,903	4,503	5,882	5,741	4,372	3,342
Gross Profit	6,582	6,010	7,521	7,461	5,725	4,996
Selling, General & Admin	2,046	1,403	1,218	1,024	784.18	695.06
Research & Development	-	-	-	103.55	110.58	141.32
Other Operating Expenses	753.09	516.59	561.82	526.62	415.35	340.68
Operating Expenses	3,479	2,465	2,259	2,045	1,626	1,412
Operating Income	3,103	3,545	5,262	5,416	4,099	3,584
Interest Expense	-89.01	-74.51	-128.11	-62.31	-91.44	-199.15
Interest & Investment Income	20.15	20.15	58.32	0.69	2.68	3.61
Earnings From Equity Investments	-	-	-	411.12	537.36	482.13
Currency Exchange Gain (Loss)	81.23	81.23	214.38	164.21	95.59	110.37
Other Non Operating Income (Expenses)	97.23	65.83	32.9	0.02	0	1.46
EBT Excluding Unusual Items	3,213	3,638	5,439	5,930	4,643	3,982
Merger & Restructuring Charges	-32.24	-32.24	-	-	-	-
Gain (Loss) on Sale of Investments	449.11	449.11	156.87	636.14	33.28	62.31
Gain (Loss) on Sale of Assets	-0.68	-0.68	-0.07	106.03	0.34	0.58
Other Unusual Items	2.73	2.73	1.17	3.73	-	-
Pretax Income	3,632	4,057	5,597	6,676	4,677	4,045
Income Tax Expense	837.61	1,054	1,484	2,138	1,053	875.1
Net Income	2,792	3,003	4,113	4,538	3,623	3,170
Net Income to Common	2,792	3,003	4,113	4,538	3,623	3,170
Net Income Growth	-24.71%	-26.99%	-9.37%	25.24%	14.30%	20.87%
Shares Outstanding (Basic)	255	255	255	255	255	255
Shares Outstanding (Diluted)	255	255	255	255	255	255
Shares Change (YoY)	0.37%	-	-	-	-0.00%	0.00%
EPS (Basic)	10.97	11.80	16.16	17.83	14.23	12.45
EPS (Diluted)	10.93	11.80	16.16	17.83	14.23	12.45
EPS Growth	-24.96%	-26.99%	-9.37%	25.28%	14.30%	20.85%
Free Cash Flow	-	3,067	1,713	2,548	2,717	3,039
Free Cash Flow Per Share	-	12.05	6.73	10.01	10.67	11.94
Dividend Per Share	-	-	-	2.000	2.000	1.250
Dividend Growth	-	-	-	0%	60.00%	-30.56%
Gross Margin	62.78%	57.17%	56.11%	56.51%	56.70%	59.92%
Operating Margin	29.60%	33.72%	39.26%	41.03%	40.59%	42.98%
Profit Margin	26.63%	28.56%	30.69%	34.37%	35.89%	38.02%
Free Cash Flow Margin	-	29.17%	12.78%	19.30%	26.91%	36.44%
EBITDA	3,661	4,063	5,726	5,795	4,407	3,817
EBITDA Margin	34.92%	38.65%	42.72%	43.89%	43.65%	45.78%
D&A For EBITDA	558.15	518.06	464.6	378.64	308.36	233.32
EBIT	3,103	3,545	5,262	5,416	4,099	3,584
EBIT Margin	29.60%	33.72%	39.26%	41.03%	40.59%	42.98%
Effective Tax Rate	23.06%	25.98%	26.52%	32.02%	22.52%	21.63%
Revenue as Reported	11,135	11,133	13,867	14,126	10,240	8,519
Advertising Expenses	-	34.78	34.89	18.83	18.37	36.04

Source: S&P Capital IQ. Standard template. Financial Sources.